कोशिश गोल्ड - मुक्त
Crucial to see who’s driving the share prices, says McKinsey’s Koller
Mint Ahmedabad
|December 08, 2025
"I don't know, and it is hard to say,” says Tim Koller when asked about the possibility of a ninth edition of Valuation, the celebrated book he coauthored with Marc Goedhart and David Wessels.
Now in its eighth edition, the 952-page volume has become a staple in boardrooms and business schools alike, shaping how corporate leaders think about value creation, and has sold over 1 million copies worldwide—a rare feat for a corporate finance text.
As he approaches retirement from McKinsey & Co. in February, Koller hopes his colleagues will continue championing what he sees as the core of sound decision-making: pursuing growth only when it delivers strong and sustainable returns on capital.
In a conversation with Mint, the valuation expert reflects on heated equity markets, the rise of retail investing and the myths that still cloud our understanding of performance, while reminding companies that long-term value still depends on fundamentals, not momentum. Company leadership should pursue the “right balance” between ‘growth and return on capital’ to drive valuation, he says, adding that profits must be sustainable and capital must be allocated and reallocated to strategic growth opportunities. Edited excerpts from the interview:
This is also compounded by the fact that smart investors are selling their stakes in these startups, whereas small investors are buying in. Do you foresee a scenario where the small investors will hold the can?
The most crucial thing to look at is who's driving the share prices. If you look at the mega seven companies in the US, you'll see that the percentage of shares owned by retail investors is about double that of most companies. So, the share prices are being driven by relatively unsophisticated investors. And so that's when you have to be cautious.
यह कहानी Mint Ahmedabad के December 08, 2025 संस्करण से ली गई है।
हजारों चुनिंदा प्रीमियम कहानियों और 10,000 से अधिक पत्रिकाओं और समाचार पत्रों तक पहुंचने के लिए मैगज़्टर गोल्ड की सदस्यता लें।
क्या आप पहले से ही ग्राहक हैं? साइन इन करें
Mint Ahmedabad से और कहानियाँ
Mint Ahmedabad
'If you're on trend, you are in trouble'
Patou creative head Guillaume Henry discusses the essence of couture and why simple is best
4 mins
December 13, 2025
Mint Ahmedabad
GST cuts, easing inflation drive rural demand revival
India’s rural economy expanded and recovered strongly in late 2025, with consumption, incomes and investment improving after a key tax reform and as inflation eased, a survey showed.
2 mins
December 13, 2025
Mint Ahmedabad
Chair man, of the bored
STREAM OF STORIES
3 mins
December 13, 2025
Mint Ahmedabad
Anju Dodiya creates disquieting worlds
Artist Anju Dodiya discusses the ideas, influences and inspiration behind her new solo show, 'The Geometry of Ash'
5 mins
December 13, 2025
Mint Ahmedabad
Bar hopping with Lounge
\"The things that make a cocktail really great are often very simple details—the frozen glass, the lemon twist—that transform two fingers of alcohol into an ice-glazed elixir,\" writes Alice Lascelles in her excellent guide to making cocktails at home, The Cocktail Edit.
1 mins
December 13, 2025
Mint Ahmedabad
New Delhi and France revise 1992 tax treaty
India and France have struck a deal to revise their 1992 treaty which will halve the tax on dividends paid by Indian units to French parents, potentially saving millions for companies with major operations in the South Asian nation, documents show.
1 min
December 13, 2025
Mint Ahmedabad
Ozempic debuts with a ₹2,200-a-week price tag
for chronic weight management, Novo Nordisk is positioning Ozempic as a treatment of type 2 diabetes with weight loss benefits, competing with Eli Lily’s Mounjaro that was launched in India in March.
1 mins
December 13, 2025
Mint Ahmedabad
How 'puri-aloo' and 'chaat' unite Lucknow
Whenever my friends want to eat puri-aloo, they invite themselves over to my home.
5 mins
December 13, 2025
Mint Ahmedabad
Novo Nordisk debuts Ozempic at ₹2,200 a week
Danish drugmaker Novo Nordisk on Friday launched its blockbuster diabetes drug Ozempic in India, with a starting price of ₹2,200 per week.
1 mins
December 13, 2025
Mint Ahmedabad
Govt’s insurance reform allows 100% FDI, composite licences
The government has paved the way for 100% foreign direct investment in the insurance sector, composite licences and easier capital requirements, among others sweeping reforms, as the Union cabinet cleared the enabling legislation, said two officials aware of the matter.
1 mins
December 13, 2025
Listen
Translate
Change font size
